Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Linzagolix→

Linzagolix Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
935283-04-8
Molecular formula
C22H15F3N2O7S
Molecular weight
508.4 g/mol
Drug class
Non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonistanti-gonadotropin
Mechanism of action
Competitively binds pituitary GnRH receptors and inhibits endogenous GnRH signalling, reducing LH and FSH secretion and producing dose-dependent suppression of ovarian oestradiol and progesterone.
Indications / reported uses
  • Treatment of moderate-to-severe symptoms associated with uterine fibroids in adult women of reproductive age, under the applicable product authorisation.
  • Treatment of endometriosis-associated symptoms where authorised by the relevant product label.

Sources: https://www.medicines.org.uk/emc/product/100020/smpc · https://www.cancer.gov/publications/dictionaries/cancer-drug/def/linzagolix

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Linzagolix Environmental Risk Assessment (ERA) (the Linzagolix ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.